Oxazepam

Oxazepam (marketed under brand names Alepam, Murelax, Oxascand, Serax, Serepax, Seresta, Sobril) is a drug which is a skeletal muscle relaxant properties.

Pharmacology

Oxazepam is a "classical" benzodiazepine, other classical benzodiazepines include; GABA to the GABA_A receptor which results in inhibitory effects on the central nervous system.^[2][3] The half life of oxazepam is 4-15 hours.^[4] Oxazepam has been shown to suppress cortisol levels.^[5]

Oxazepam is an active metabolite formed during the breakdown of lorazepam in this respect. (1) There is preferential storage of oxazepam in some organs including the heart. Absorption by any administered route and the risk of accumulation is significantly increased in the neonate and there is clinical justification to recommend the withdrawal of oxazepam during pregnancy and breast feeding as oxazepam is excreted in breast milk.^[6]

Indications

It is an intermediate acting benzodiazepine with a slow onset of action, so it is usually prescribed to individuals who have trouble staying asleep, rather than falling asleep. It is commonly prescribed for anxiety disorders with associated tension, irritability, and agitation. It is also prescribed for drug and alcohol withdrawal, and for anxiety associated with depression. Also prescribed for sleepwalking before a neurologist is involved when the sleepwalker may be a problem or danger to themselves.  

Tolerance

When tolerance and habituation occurs brain concentration of oxazepam increase according to degree of tolerance.^[7]

Dependence

Oxazepam as with other barbiturate withdrawal. The higher the dose and the longer the drug is taken the greater the risk of experiencing unpleasant withdrawal symptoms. Withdrawal symptoms can however occur at standard dosages and also after short term use. Benzodiazepine treatment should be discontinued as soon as possible via a slow and gradual dose reduction regime.^[8]

The Committee on the Review of Medicines

The Committee on the Review of Medicines (UK) carried out a review into benzodiazepines due to significant concerns of tolerance, drug dependence and benzodiazepine withdrawal problems and other adverse effects. The committee found that benzodiazepines do not have any benzodiazepine withdrawal syndrome including symptoms such as anxiety, apprehension, tremor, insomnia, nausea, and vomiting upon cessation of benzodiazepine use. Withdrawal symptoms tended to develop within 24 hours on the cessation of a short acting benzodiazepine and within 3 - 10 days after the cessation of a more short acting benzodiazepine. Withdrawal effects could occur after treatment lasting only 2 weeks at therapeutic dose levels however withdrawal effects tended to occur with habitual use beyond 2 weeks and were more likely the higher the dose. The withdrawal symptoms may appear to be similar to the original condition. The committee recommended that all benzodiazepine treatment be withdrawn gradually and recommended that benzodiazepine treatment be used only in carefully selected patients and that therapy be limited to short term use only. It was noted in the review that alcohol can potentiate the central nervous system depressant effects of benzodiazepines and should be avoided. The central nervous system depressant effects of benzodiazepines may make driving or operating machinery dangerous and the elderly are more prone to these adverse effects. In the neonate high single doses or repeated low doses have been reported to produce hypotonia, poor sucking, and hypothermia in the neonate and irregularities in the fetal heart. Benzodiazepines should be avoided in lactation. Withdrawal from benzodiazepines should be gradual as abrupt withdrawal from high doses of benzodiazepines may cause confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. Abrupt withdrawal from lower doses may cause depression, nervousness, rebound insomnia, irritability, sweating, and diarrhoea.^[9]

Dosage

• Mild/moderate anxiety - 10 to 15mg, 3 to 4 times daily
• Severe anxiety - 15 to 30mg, 3 to 4 times daily
• Symptoms related to alcohol withdrawal - 15 to 30mg, 3 to 4 times daily

Availability

In the United Kingdom, oxazepam is available generically in the form of 10mg, 15mg and 30mg tablets.

Side effects

The side effects of oxazepam are similar in nature to those of other benzodiazepines.

Side effects from oxazepam are common and include: drowsiness, dizziness, tiredness, weakness, dry mouth, diarrhea, upset stomach, changes in appetite, heart palpitations, anxiety, trouble breathing, shortness of breath, angry outbursts, trouble sleeping, tremors

Internal tremors have been alleviated by using 15mg of oxazepam as required, usually approximately four hourly.

Interactions

As oxazepam is an active metabolite of benzodiazepines) are interacting in a way, that is difficult to pre-estimate, concomitant use of oxazepam and alcohol can lead to increased sedation, severe problems with coordination (ataxiae), decreased muscle tone and in severe cases or in predisposed patients even to life-threatening intoxications with coma and collapse. Concomitant use of alcohol and oxazepam (as well as other benzodiazepines) also increases the risk of an addiction. Benzodiazepines including oxazepam may inhibit the glucuronidation of morphine leading to increased levels of and prolongation of the effects of morphine.^[10]

Special precautions

Benzodiazepines including oxazepam are lipophilic drugs and rapidly penetrate membranes and therefore rapidly cross over into the placenta with significant uptake of the drug. Use of benzodiazepines in late pregnancy especially high doses may result in floppy infant syndrome.^[11]

Pregnancy

There is inconclusive evidence that benzodiazepines including oxazepam if taken early in pregnancy may result in reduced IQ, neurodevelopmental problems, physical malformations in cardiac or facial structure as well as other malformations in some new borns. Oxazepam when taken during late in pregnancy, the third trimester, causes a definite risk to the neonate including a severe metabolic responses to cold stress. Floppy infant syndrome and sedation in the new born may also occur. Symptoms of floppy infant syndrome and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.^[12]

Carcinogenicity

Oxazepam is listed a possible Group 2b) by the IARC.

Contraindications

Overdose

Oxazepam is a drug which is very frequently involved in drug intoxication, including overdose.^[13] Oxazepam overdose has been involved in fatal overdoses in an Australian study of drug related deaths. Benzodiazepines were found to be the sole cause of death in one third of cases.^[14]

Symptoms of overdose include:

• Somnolence
• Confusion
• Impaired motor function
• Coma
• Hypoventilation (respiratory depression)
• Hypotension

Abuse

Benzodiazepines, including flunitrazepam account for the largest volume of forged drug prescriptions in Sweden, a total of 52% of drug forgeries being for benzodiazepines, suggesting benzodiazepines are a major prescription drug class of abuse.^[15]

Legal Status

Oxazepam is a Schedule IV drug under the Convention on Psychotropic Substances [1].

Usage

Oxazepam along with diazepam, nitrazepam and temazepam represent 82% of the benzodiazepine market in Australia.^[16]

References

1. ^ Braestrup C; Squires RF. (Apr 1978). "Pharmacological characterization of benzodiazepine receptors in the brain.". Eur J Pharmacol 48 (3): 263-70. PMID 639854.
2. ^ Skerritt JH; Johnston GA. (6). "Enhancement of GABA binding by benzodiazepines and related anxiolytics.". Eur J Pharmacol. 89 (3-4): 193-8. PMID 6135616.
3. ^ Oelschläger H. (4). "[Chemical and pharmacologic aspects of benzodiazepines]". Schweiz Rundsch Med Prax. 78 (27-28): 766-72. PMID 2570451.
4. ^ Professor heather Ashton (April 2007). BENZODIAZEPINE EQUIVALENCY TABLE. Retrieved on Sept 23, 2007.
5. ^ Christensen P; Lolk A, Gram LF, Kragh-Sørensen P. (1992). "Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers.". Psychopharmacology. 106 (4): 511-6. PMID 1349754.
6. ^ Olive G; Dreux C. (Jan 1977). "Pharmacologic bases of use of benzodiazepines in peréinatal medicine.". Arch Fr Pediatr. 34(1): 74-89. PMID 851373.
7. ^ Chodera A; Szczawińska K, Cenajek D, Nowakowska E. (Jul-Aug 1984). "Pharmacokinetic aspects of habituation to benzodiazepines.". Pol J Pharmacol Pharm. 36 (4): 353-60. PMID 6152051.
8. ^ MacKinnon GL; Parker WA. (1982). "Benzodiazepine withdrawal syndrome: a literature review and evaluation.". The American journal of drug and alcohol abuse. 9 (1): 19-33. PMID 6133446.
9. ^ Committee on the Review of Medicines (29). "Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines." (pdf). Br Med J. 280 (6218): 910-2. PMID 7388368.
10. ^ Pacifici GM; Gustafsson LL, Säwe J, Rane A. (Apr 1986). "Metabolic interaction between morphine and various benzodiazepines.". Acta Pharmacol Toxicol (Copenh). 58 (4): 249-52. PMID 2872767.
11. ^ Kanto JH. (May 1982). "Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.". Drugs. 23 (5): 354-80. PMID 6124415.
12. ^ McElhatton PR. (Nov-Dec 1994). "The effects of benzodiazepine use during pregnancy and lactation.". Reprod Toxicol. 8 (6): 461-75. PMID 7881198.
13. ^ Zevzikovas A; Kiliuviene G, Ivanauskas L, Dirse V. (2002). "[Analysis of benzodiazepine derivative mixture by gas-liquid chromatography]". Medicina (Kaunas). 38 (3): 316-20. PMID 12474705.
14. ^ Drummer OH; Ranson DL. (Dec 1996). "Sudden death and benzodiazepines.". Am J Forensic Med Pathol. 17 (4): 336-42. PMID 8947361.
15. ^ Bergman U; Dahl-Puustinen ML. (1989). "Use of prescription forgeries in a drug abuse surveillance network.". Eur J Clin Pharmacol. 36 (6): 621-3. PMID 2776820.
16. ^ Mant A; Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D. (Dec 1993). "Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database.". Aust J Public Health. 17 (4): 345-9. PMID 7911332.